Literature DB >> 16006497

Do herpes zoster patients receive antivirals? A Dutch National Survey in General Practice.

Wim Opstelten1, Gerrit A van Essen, Karel G M Moons, Albert J M van Wijck, François G Schellevis, Cornelis J Kalkman, Theo J M Verheij.   

Abstract

BACKGROUND: The main complications of herpes zoster (HZ) are postherpetic neuralgia and, in case of HZ ophthalmicus, eye disorders. Antiviral treatment may modify the course of disease and reduce the risk of complications.
OBJECTIVE: To assess which doctors' and patients' characteristics were related to prescription of antiviral therapy for HZ.
METHODS: Ninety general practices (358 008 patients) in The Netherlands registered all patient contacts in a database for one year as part of the Second Dutch National Survey of General Practice. The present study used ICPC code S70 to search that database for patients with a new diagnosis of HZ. The full-text medical records of the selected patients were then reviewed and the potential determinants for the prescription of antiviral drugs (including characteristics of patients, GPs, and practices) analysed using multilevel logistic regression modelling.
RESULTS: Of the 1129 patients diagnosed with HZ (incidence 3.2/1000 patients/year), 22.5% received antiviral drugs. Independent determinants for prescription of antiviral therapy were age [45-54 years: adjusted odds ratio (OR) 2.9 (95% CI 1.6-5.0); 55-64 years: OR 4.2 (95% CI 2.4-7.6); 65-74 years: OR 5.1 (95% CI 2.7-9.6); > or =75 years: OR 8.1 (95% CI 4.4-15.1)], ophthalmic localisation of the shingles (OR 3.2, 95% CI 1.6-6.7), and the presence of asthma/COPD (OR 1.6, 95% CI 1.0-2.6). GPs who reported to strongly adhere to professional guidelines prescribe more frequently antiviral drugs (OR 1.9, 95% CI 1.2-3.1).
CONCLUSIONS: A minority of HZ patients were prescribed antiviral treatment. Increasing age, ophthalmic localisation, presence of asthma/COPD, and adherence to professional guidelines were factors favouring prescription. More information on the determinants of GPs' treatment decisions is necessary for successful implementation of HZ guidelines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16006497     DOI: 10.1093/fampra/cmi055

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  9 in total

1.  Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Authors:  Ralph P Insinga; Robbin F Itzler; James M Pellissier
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.

Authors:  Leonardo Emberti Gialloreti; Monica Merito; Patrizio Pezzotti; Luigi Naldi; Antonio Gatti; Maud Beillat; Laurence Serradell; Rafaelle di Marzo; Antonio Volpi
Journal:  BMC Infect Dis       Date:  2010-08-03       Impact factor: 3.090

3.  A systematic literature review of herpes zoster incidence worldwide.

Authors:  Désirée van Oorschot; Hilde Vroling; Eveline Bunge; John Diaz-Decaro; Desmond Curran; Barbara Yawn
Journal:  Hum Vaccin Immunother       Date:  2021-03-02       Impact factor: 3.452

4.  Burden of herpes zoster-associated chronic pain in Italian patients aged 50 years and over (2009-2010): a GP-based prospective cohort study.

Authors:  Hélène Bricout; Emilia Perinetti; Paolo Marchettini; Pietro Ragni; Carla Maria Zotti; Giovanni Gabutti; Antonio Volpi; Elisabetta Franco
Journal:  BMC Infect Dis       Date:  2014-12-06       Impact factor: 3.090

Review 5.  Eye and Periocular Skin Involvement in Herpes Zoster Infection.

Authors:  Chris D Kalogeropoulos; Ioannis D Bassukas; Marilita M Moschos; Khalid F Tabbara
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2015

Review 6.  Postherpetic neuralgia in the elderly.

Authors:  R W Johnson; J McElhaney
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

7.  Prescription of antiviral therapy after herpes zoster in general practice: who receives therapy?

Authors:  Harriet J Forbes; Sara L Thomas; Liam Smeeth; Sinéad M Langan
Journal:  Br J Gen Pract       Date:  2012-12       Impact factor: 5.386

8.  Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands.

Authors:  Jorien G J Pierik; Pearl D Gumbs; Sander A C Fortanier; Pauline C E Van Steenwijk; Maarten J Postma
Journal:  BMC Infect Dis       Date:  2012-05-10       Impact factor: 3.090

9.  Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005.

Authors:  Gillian C Hall; Dawn Carroll; Henry J McQuay
Journal:  BMC Fam Pract       Date:  2008-05-06       Impact factor: 2.497

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.